Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969195 | 0.77 | KMT2A (0.36) | KDM4EALDH1A1CHRM2CHRM1 | |
| SCHEMBL608303 | 0.75 | RAD52 (0.53) | KDM4EHTT | |
| SCHEMBL10979646 | 0.75 | CA1 (0.39) | HTR2AHTR2CKCNH2ALDH1A1CHRM2 | |
| SCHEMBL10974784 | 0.73 | CA1 (0.39) | HTR2AHTR2CKCNH2ALDH1A1CHRM2 | |
| SCHEMBL350930 | 0.71 | SLC18A3 (0.44) | KDM4EGRIN2B | |
| SCHEMBL1714647 | 0.71 | HTR2C (0.41) | HTR2AHTR2CKCNH2ALDH1A1DRD2 | |
| SCHEMBL9185398 | 0.70 | PKM (0.42) | HTR2AHTR2CKCNH2ALDH1A1CHRM2 | |
| SCHEMBL10630089 | 0.70 | SLC18A3 (0.43) | KDM4EHTTGRIN2BGRIN1ALDH1A1 | |
| SCHEMBL10632309 | 0.69 | SLC18A3 (0.43) | KDM4EHTTGRIN2B | |
| Hydrochloric Acid SCHEMBL10632236 | 0.69 | SLC18A3 (0.43) | KDM4EHTTGRIN2BGRIN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102712587-A | Novel ethane diamine hepcidin antagonists | VIFOR INT AG | 2012-10-03 | — | — | CN | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | KDM4E 1676/4885HTT 2331/4885GRIN2B 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.